AbbVie Gains CHMP Positive Opinion for Upadacitinib in Non-Segmental Vitiligo Across EU

A positive CHMP opinion for upadacitinib (RINVOQ®; 15 mg, once daily) in non-segmental vitiligo positions AbbVie to add a ninth EU indication to a single molecule already spanning eight approved conditions, a manufacturing and lifecycle management challenge that will land squarely on plant heads and supply planners before the European Commission issues its final decision, expected within months.

The opinion, adopted by the European Medicines Agency's Committee for Medicinal Products for Human Use, is supported by data from the Phase 3 Viti-Up program: two replicate, randomized, placebo-controlled, double-blind studies in adult and adolescent patients with NSV. Upadacitinib 15 mg met both co-primary endpoints at week 48, at least 50% improvement in total body repigmentation (T-VASI 50) and at least 75% improvement in facial repigmentation (F-VASI 75) from baseline. Key secondary endpoints were also achieved, and the safety profile was consistent with approved indications, with no new signals identified.

If the European Commission converts the opinion to a formal approval, upadacitinib would become the first systemic medicine specifically indicated for non-segmental vitiligo, the most prevalent form of the disease, affecting approximately 84% of vitiligo patients. Current EU-approved indications for upadacitinib include atopic dermatitis, rheumatoid arthritis, psoriatic arthritis, radiographic and non-radiographic axial spondylarthritis, ulcerative colitis, Crohn's disease, and giant cell arteritis, a breadth that already demands rigorous process validation and batch release discipline across a multi-indication supply chain.

For QA directors and regulatory affairs leads, the compliance read centres on label management and post-approval commitments. Expanding a JAK inhibitor's indication set within the EU requires updated risk management documentation and, depending on the final EC decision text, potential revisions to existing 21 CFR Part 211-equivalent GMP records for markets where AbbVie operates under dual regulatory frameworks. The Viti-Up program remains ongoing, meaning additional data packages may feed into post-marketing obligations under ICH Q10 pharmaceutical quality system requirements.

The sterility assurance and cold-chain parameters for the 15 mg oral formulation are unchanged, but demand forecasting for a condition with an unpredictable patient identification curve, NSV progresses asymmetrically and is frequently misclassified as a cosmetic disorder, introduces supply variability that procurement and manufacturing teams will need to model ahead of launch readiness.

The measurable checkpoint for operations teams is the European Commission decision timeline, against which batch release schedules, distribution agreements, and label artwork change controls must be sequenced.

Source: AbbVie News Center via PR Newswire, 29 June 2026.